139 related articles for article (PubMed ID: 22812184)
41. Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.
Zeng Z; Tu J; Cheng J; Yao M; Wu Y; Huang X; Xie X; Zhang X; Lu F; Chen X
Tumour Biol; 2015 Sep; 36(9):6891-900. PubMed ID: 25851350
[TBL] [Abstract][Full Text] [Related]
42. Breast cancer and cyclin D1 gene polymorphism in Turkish women.
Yaylim-Eraltan I; Ergen A; Görmüs U; Arikan S; Küçücük S; Sahin O; Yigit N; Yildiz Y; Isbir T
In Vivo; 2009; 23(5):767-72. PubMed ID: 19779113
[TBL] [Abstract][Full Text] [Related]
43. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
44. Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis.
Yang M; Zhu H; Hu T; Liu S; Wang H
Int J Clin Exp Med; 2015; 8(8):12983-8. PubMed ID: 26550218
[TBL] [Abstract][Full Text] [Related]
45. Association of cyclin D1 variants with head and neck cancer susceptibility: evidence from a meta-analysis.
Lin H; Fang L; Lin D
Asian Pac J Cancer Prev; 2014; 15(14):5645-51. PubMed ID: 25081680
[TBL] [Abstract][Full Text] [Related]
46. The CCND1 G870A gene polymorphism and leukemia or non-Hodgkin lymphoma risk: a meta-analysis.
Qin LY; Zhao LG; Chen X; Yang Z; Mo WN
Asian Pac J Cancer Prev; 2014; 15(16):6923-8. PubMed ID: 25169547
[TBL] [Abstract][Full Text] [Related]
47. The CCND1 G870A gene polymorphism and brain tumor risk: a meta-analysis.
Qin LY; Zhao LG; Chen X; Li P; Yang Z; Mo WN
Asian Pac J Cancer Prev; 2014; 15(8):3607-12. PubMed ID: 24870765
[TBL] [Abstract][Full Text] [Related]
48. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.
Xue Y; Rong L; Tong N; Wang M; Zhang Z; Fang Y
Int J Clin Exp Pathol; 2015; 8(9):11594-600. PubMed ID: 26617896
[TBL] [Abstract][Full Text] [Related]
49. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry.
Bachmann K; Neumann A; Hinsch A; Nentwich MF; El Gammal AT; Vashist Y; Perez D; Bockhorn M; Izbicki JR; Mann O
J Surg Oncol; 2015 Mar; 111(3):316-23. PubMed ID: 25470788
[TBL] [Abstract][Full Text] [Related]
50. The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations.
Zhang LQ; Huang XE; Wang J; Shang JQ; Bai J; Liu FY; Guan X; Zhou JN
Asian Pac J Cancer Prev; 2011; 12(1):81-5. PubMed ID: 21517236
[TBL] [Abstract][Full Text] [Related]
51. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis.
Pabalan N; Bapat B; Sung L; Jarjanazi H; Francisco-Pabalan O; Ozcelik H
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2773-81. PubMed ID: 18843022
[TBL] [Abstract][Full Text] [Related]
52. Genetic polymorphism of
He W; Zeng Y; Long J; Zhou Q; Hu Y; Chen M
Biomed Rep; 2013 Mar; 1(2):303-307. PubMed ID: 24648939
[TBL] [Abstract][Full Text] [Related]
53. Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis.
Soleimani Z; Kheirkhah D; Sharif MR; Sharif A; Karimian M; Aftabi Y
Pathol Oncol Res; 2017 Jul; 23(3):621-631. PubMed ID: 28004353
[TBL] [Abstract][Full Text] [Related]
54. Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case-control studies.
Wang Y; Li Z; Liu N; Zhang G
Tumour Biol; 2014 Apr; 35(4):3155-65. PubMed ID: 24264314
[TBL] [Abstract][Full Text] [Related]
55. Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects.
Zhuo XL; Ling JJ; Zhao HY; Zhou Y; Song YF; Tan YH
Exp Ther Med; 2012 Oct; 4(4):748-754. PubMed ID: 23170138
[TBL] [Abstract][Full Text] [Related]
56. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
57. The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis.
Zhou C; An H; Hu M; Liu Q; Geng P; Xu J; Sun B; Liu C
Tumour Biol; 2013 Dec; 34(6):3831-7. PubMed ID: 23873109
[TBL] [Abstract][Full Text] [Related]
58. Cyclin D1 G870A polymorphism: Association with uterine leiomyoma risk and
Salimi S; Shahrakipour M; Hajizadeh A; Mokhtari M; Mousavi M; Teimoori B; Yaghmaei M
Biomed Rep; 2017 Feb; 6(2):237-241. PubMed ID: 28357079
[TBL] [Abstract][Full Text] [Related]
59. Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma.
Atac A; Riecke B; Assaf AT; Gröbe A; Friedrich RE; Heiland M; Izbicki JR; Kluwe L; Blessmann M
Anticancer Res; 2014 Jan; 34(1):235-8. PubMed ID: 24403468
[TBL] [Abstract][Full Text] [Related]
60. Cyclin D1 G870A Polymorphism: Relation to the Risk of ALL Development, Prognosis Impact, and Methotrexate Cytotoxicity.
El Menshawy N; El Marghany AB; Sarhan MM; Aladle DA
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2941-2947. PubMed ID: 33112552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
